Avid Bioservices Inc (CDMO)

[exwannabe]

Peregrine’s ongoing n=121 2nd-Line NSCLC Trial = “essentially a registrational Ph.2 design”…

Isn't this kind of moot point now.

By my math the primary endpoint (ORR) was not even close to stat sig.

3mg vs placebo: 7 (n=39) (17.9%) vs 3 (n=38) (7.9%) p=.31

1mg vs placebo: 6 (n=40) (15%) vs 3 (n=38) (7.9%) p=.48

Even if OS were to be stat sig (which seams highly unlike with the trial size), it would be pointless to file with this data.